Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC
Title:
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC
Author:
Cho, B.C. Reinmuth, N. Lee, K.H. Ahn, M.-J. Luft, A. Van den Heuvel, M. Dols, M. Cobo Smolin, A. Vicente, D. Moiseyenko, V. Antonia, S.J. Moulec, S. Le Robinet, G. Natale, R. Garon, E.B. Nakagawa, K. Liu, F. Thiyagarajah, P. Peters, S. Rizvi, N.A.